Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2016
|
Wendell Peter C Director |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$295,000
$59.5 P/Share
|
|
Nov 02
2016
|
Wendell Peter C Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$255,000
$51.86 P/Share
|
|
Nov 02
2016
|
Rochelle B Lazarus Director |
SELL
Open market or private sale
|
Direct |
20,000
-81.32%
|
$1,180,000
$59.06 P/Share
|
|
Nov 02
2016
|
Rochelle B Lazarus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.25%
|
$740,000
$37.35 P/Share
|
|
Oct 03
2016
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
40,800
-31.63%
|
$2,529,600
$62.07 P/Share
|
|
Oct 03
2016
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Exercise of conversion of derivative security
|
Direct |
40,800
+24.03%
|
$1,795,200
$44.19 P/Share
|
|
Sep 01
2016
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
39,200
-100.0%
|
$2,430,400
$62.61 P/Share
|
|
Sep 01
2016
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
39,200
+50.0%
|
$1,293,600
$33.49 P/Share
|
|
Aug 10
2016
|
Clark Golestani EVP & Chief Info Officer |
SELL
Open market or private sale
|
Direct |
3,000
-17.56%
|
$189,000
$63.03 P/Share
|
|
Aug 05
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
392,000
-16.46%
|
$23,912,000
$61.95 P/Share
|
|
Aug 05
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
392,000
+19.16%
|
$12,936,000
$33.88 P/Share
|
|
Aug 04
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,000
-28.14%
|
$399,000
$57.8 P/Share
|
|
Aug 02
2016
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Payment of exercise price or tax liability
|
Direct |
1,619
-4.31%
|
$93,902
$58.66 P/Share
|
|
Aug 02
2016
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
5,150
+12.06%
|
-
|
|
Aug 02
2016
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
13,600
-2.6%
|
-
|
|
Jul 05
2016
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
45,000
-18.02%
|
$2,565,000
$57.96 P/Share
|
|
Jul 05
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
27,621
-5.02%
|
$1,602,018
$58.0 P/Share
|
|
Jul 05
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
27,621
+4.78%
|
$1,408,671
$51.02 P/Share
|
|
Jul 01
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
32,379
-5.84%
|
$1,877,982
$58.0 P/Share
|
|
Jul 01
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
32,379
+5.51%
|
$1,651,329
$51.02 P/Share
|
|
Jul 01
2016
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
30,000
-18.5%
|
$1,710,000
$57.49 P/Share
|
|
Jul 01
2016
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+15.61%
|
$1,200,000
$40.7 P/Share
|
|
Jul 01
2016
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$2,850,000
$57.69 P/Share
|
|
Jul 01
2016
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$2,200,000
$44.3 P/Share
|
|
May 20
2016
|
Clark Golestani EVP & Chief Info Officer |
SELL
Open market or private sale
|
Direct |
38,647
-69.35%
|
$2,086,938
$54.8 P/Share
|
|
May 20
2016
|
Clark Golestani EVP & Chief Info Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,647
+40.95%
|
$1,700,468
$44.98 P/Share
|
|
May 19
2016
|
Clark Golestani EVP & Chief Info Officer |
SELL
Open market or private sale
|
Direct |
1,230
-6.72%
|
$66,420
$54.55 P/Share
|
|
May 10
2016
|
Michael J Holston EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
100,021
-60.88%
|
$5,401,134
$54.5 P/Share
|
|
May 10
2016
|
Michael J Holston EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
100,021
+26.35%
|
$4,400,924
$44.63 P/Share
|
|
May 06
2016
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Payment of exercise price or tax liability
|
Direct |
1,258
-3.76%
|
$67,932
$54.09 P/Share
|
|
May 06
2016
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
4,002
+10.69%
|
-
|
|
May 06
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,566
-3.89%
|
$84,564
$54.09 P/Share
|
|
May 06
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,002
+9.05%
|
-
|
|
May 06
2016
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
746
-4.85%
|
$40,284
$54.09 P/Share
|
|
May 06
2016
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,001
+11.52%
|
-
|
|
May 06
2016
|
Roger M Perlmutter Exe V-P & Pres, MRL |
SELL
Payment of exercise price or tax liability
|
Direct |
26,946
-28.39%
|
$1,455,084
$54.09 P/Share
|
|
May 06
2016
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Exercise of conversion of derivative security
|
Direct |
44,464
+31.91%
|
-
|
|
May 06
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,243
-4.79%
|
$67,122
$54.09 P/Share
|
|
May 06
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,335
+11.4%
|
-
|
|
Apr 14
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
131,040
-20.05%
|
$7,338,240
$56.11 P/Share
|
|
Apr 14
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
131,040
+16.7%
|
$5,765,760
$44.19 P/Share
|
|
Apr 13
2016
|
William B Harrison Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.36%
|
$170,000
$34.44 P/Share
|
|
Feb 22
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,537
+10.17%
|
$126,850
$50.77 P/Share
|
|
Feb 22
2016
|
Willie A Deese Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
14,557
+9.81%
|
$727,850
$50.77 P/Share
|
|
Feb 22
2016
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
11,332
+32.46%
|
$566,600
$50.77 P/Share
|
|
Feb 22
2016
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
93,241
+15.14%
|
$4,662,050
$50.77 P/Share
|
|
Feb 22
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,377
+8.58%
|
$168,850
$50.77 P/Share
|
|
Feb 22
2016
|
Clark Golestani EVP & Chief Info Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,150
+25.14%
|
$307,500
$50.77 P/Share
|
|
Feb 22
2016
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
16,326
+11.08%
|
$816,300
$50.77 P/Share
|
|
Feb 22
2016
|
Michael J Holston EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,443
+15.15%
|
$572,150
$50.77 P/Share
|